Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
(OSI) Prosidion is developing PSN-9301, a rationally designed dipeptidyl peptidase IV inhibitor acquired from Probiodrug AG, as a potential oral treatment for type 2 diabetes. Phase II clinical trials of PSN-9301 are underway.
Epstein
Benjamin J
BJ
University of Florida, Department of Pharmacy Practice and Division of Internal Medicine, College of Pharmacy, HPNP Building, Room 3316, 101 South Newell Drive, Gainesville, FL 32610-0486, USA. epstein@cop.ufl.edu
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents